Development of in vivo Biomarkers for Progressive Tau Pathology after Traumatic Brain Injury
Technical Report,15 Jan 2013,28 Feb 2019
Texas, University of, Southwestern Medical Center at Dallas Dallas United States
Pagination or Media Count:
To assess extracts from the brains of human tau transgenic mice subjected to experimental traumatic brain injury for tau aggregating activity in a cell-based assay. To determine whether mouse blood and cerebrospinal fluid tau aggregating activity quantitatively predicts brain tau pathology and neurodegeneration in mouse models of chronic traumatic encephalopathy. To test whether antibodies that block tau aggregating activity and propagation of aggregates in cultured cell-based assays also block tau pathology and neurodegeneration in mouse models of chronic traumatic encephalopathy. This could lead to future therapeutic targets. To develop an antibody-based assay for tau aggregating activity to complement the cell-based assay.
- Medicine and Medical Research